Boston settles Guidant spat with JNJ and emerges not too dented
This article was originally published in Clinica
Executive Summary
Boston Scientific and Johnson & Johnson have finally buried the hatchet in their longstanding dispute ignited by an intense bidding war for cardiovascular device firm Guidant in late 2005.
You may also be interested in...
Medtechs At The Wheel In New Health Care Landscape
2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.
EU Extends Provisions For Ensuring Post-Brexit Flow Of Medicines
Proposals for averting medicines supply disruptions caused by Brexit in Northern Ireland and three EU markets are about to be discussed by EU legislators.
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.